financetom
Business
financetom
/
Business
/
TE Connectivity's Fiscal Q4 Adjusted Earnings, Net Sales Increase
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
TE Connectivity's Fiscal Q4 Adjusted Earnings, Net Sales Increase
Nov 3, 2024 2:48 PM

06:33 AM EDT, 10/30/2024 (MT Newswires) -- TE Connectivity ( TEL ) reported fiscal Q4 adjusted earnings Wednesday of $1.95 per diluted share, up from $1.78 a year earlier.

Analysts polled by Capital IQ expected $1.94.

Net sales for the quarter ended Sept. 27 were $4.07 billion, up from $4.04 billion a year earlier.

Analysts surveyed by Capital IQ expected $4 billion.

For fiscal Q1, the company expects adjusted EPS of $1.88 on net sales of about $3.9 billion. Analysts polled by Capital IQ expect $1.89 on $3.94 billion.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
UnitedHealth, Amedisys waive right to terminate merger agreement
UnitedHealth, Amedisys waive right to terminate merger agreement
Dec 27, 2024
Dec 27 (Reuters) - UnitedHealth ( UNH ) and Amedisys ( AMED ) waived the right to terminate their merger agreement until a certain date, a filing showed on Friday. (Reporting by Sriparna Roy in Bengaluru; Editing by Anil D'Silva) ...
UnitedHealth, Amedisys waive right to terminate merger agreement
UnitedHealth, Amedisys waive right to terminate merger agreement
Dec 27, 2024
(Reuters) - UnitedHealth ( UNH ) and Amedisys ( AMED ) waived the right to terminate their merger agreement until a certain date, a filing showed on Friday. (Reporting by Sriparna Roy in Bengaluru; Editing by Anil D'Silva) ...
BeiGene Gets FDA Approval for Tevimbra in Stomach-Esophagus Junction Cancer
BeiGene Gets FDA Approval for Tevimbra in Stomach-Esophagus Junction Cancer
Dec 27, 2024
06:30 AM EST, 12/27/2024 (MT Newswires) -- BeiGene ( BGNE ) said Friday that its antibody drug Tevimbra has received approval from the US Food and Drug Administration for first-line treatment of stomach-esophagus junction cancer. The approved indication covers a certain type of unresectable or metastatic gastroesophageal junction adenocarcinoma, a rare cancer at the area where the esophagus connects with...
Verde AgriTech CEO Ends Automatic Securities Disposition Plan
Verde AgriTech CEO Ends Automatic Securities Disposition Plan
Dec 27, 2024
06:27 AM EST, 12/27/2024 (MT Newswires) -- Verde AgriTech ( VNPKF ) on Tuesday said President and CEO Cristiano Veloso terminated an automatic securities disposition plan. An automatic securities disposition plan is an arrangement that allows insiders to sell securities while still complying with insider trading restrictions. Veloso was not in possession of material non-public information at the time the...
Copyright 2023-2026 - www.financetom.com All Rights Reserved